Systemic Anti–PD-1 Immunotherapy Results in PD-1 Blockade on T Cells in the Cerebrospinal Fluid
Sign Up to like & getrecommendations! Published in 2020 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2020.4508
Abstract: This case series evaluates pembrolizumab concentrations and programmed cell death 1 blockade on T cells in cerebrospinal fluid after intravenous administration. read more here.
Keywords: anti immunotherapy; cells cerebrospinal; immunotherapy results; blockade cells ... See more keywords
New advances in pharmaceutical strategies for sensitizing anti-PD-1 immunotherapy and clinical research.
Sign Up to like & getrecommendations! Published in 2022 at "Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology"
DOI: 10.1002/wnan.1837
Abstract: Attempts have been made continuously to use nano-drug delivery system (NDDS) to improve the effect of antitumor therapy. In recent years, especially in the application of immunotherapy represented by antiprogrammed death receptor 1 (anti-PD-1), it… read more here.
Keywords: anti immunotherapy; advances pharmaceutical; pharmaceutical strategies; new advances ... See more keywords
Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.11.014
Abstract: Despite the marked success of applications of PD-1/PD-L1 checkpoint blockades in clinical, the efficacy and responsiveness of these agents varies greatly among different tumor types and across individual patients. Therefore, establishment of predictive biomarkers for… read more here.
Keywords: anti immunotherapy; progress challenges; provide new; challenges predictive ... See more keywords
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer letters"
DOI: 10.1016/j.canlet.2019.10.027
Abstract: Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy until now. Yet, the underlying association between KRAS mutations and immune responses remains… read more here.
Keywords: anti immunotherapy; immunogenicity; kras mutant; efficacy anti ... See more keywords
An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "mAbs"
DOI: 10.1080/19420862.2022.2088454
Abstract: ABSTRACT Monoclonal antibodies targeting the programmed cell death protein 1 (PD-1) remain the most prevalent cancer immunotherapy both as a monotherapy and in combination with additional therapies. Despite the extensive success of anti-PD-1 monoclonal antibodies… read more here.
Keywords: anti immunotherapy; immunotherapy; affinity; maximum efficacy ... See more keywords
Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2019 at "Science Advances"
DOI: 10.1126/sciadv.aav2437
Abstract: In vivo–based functional genomic screen identifies DDR2 as an important determinant of efficacy of anti–PD-1 immunotherapy. While a fraction of cancer patients treated with anti–PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need… read more here.
Keywords: anti immunotherapy; response anti; targeting ddr2; tumor ... See more keywords
Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Science Translational Medicine"
DOI: 10.1126/scitranslmed.abq7019
Abstract: The tumor-intrinsic NOD-, LRR- and pyrin domain-containing protein-3 (NLRP3) inflammasome–heat shock protein 70 (HSP70) signaling axis is triggered by CD8+ T cell cytotoxicity and contributes to the development of adaptive resistance to anti–programmed cell death… read more here.
Keywords: anti immunotherapy; hsp70 tlr4; hyperprogression; tumor ... See more keywords
HSP90 mediates IFNγ-induced adaptive resistance to anti-PD-1 immunotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer research"
DOI: 10.1158/0008-5472.can-21-3917
Abstract: Constitutive or acquired resistance is a major problem limiting the clinical success of anticancer immunotherapies targeting the PD-1/PD-L1 interaction. Here, we report that the molecular chaperone HSP90 is a key mediator of IFNγ-induced adaptive immune… read more here.
Keywords: anti immunotherapy; induced adaptive; hsp90; ifn induced ... See more keywords
Abstract 1560: Targeting RNA-binding protein HuR to improve anti-PD-1 immunotherapy response in breast cancer
Sign Up to like & getrecommendations! Published in 2021 at "Immunology"
DOI: 10.1158/1538-7445.am2021-1560
Abstract: Breast cancer has been considered as a less immune-sensitive disease. Patients with metastatic breast cancer have a particularly low objective response rate (ORR) to anti-PD-1/PD-L1 therapy (3%~24%). It will be valuable to improve the treatment… read more here.
Keywords: hur; breast cancer; anti immunotherapy; cancer ... See more keywords
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Journal for Immunotherapy of Cancer"
DOI: 10.1186/s40425-019-0650-9
Abstract: BackgroundCheckpoint-blockade immunotherapy targeting programmed cell death protein 1 (PD-1) has recently shown promising efficacy in hepatocellular carcinoma (HCC). However, the factors affecting and predicting the response to anti-PD-1 immunotherapy in HCC are still unclear. Herein,… read more here.
Keywords: anti immunotherapy; hepatocellular carcinoma; immunotherapy; gut microbiome ... See more keywords
Induction of Progenitor Exhausted Tissue-Resident Memory CD8+ T Cells Upon Salmonella Typhi Porins Adjuvant Immunization Correlates With Melanoma Control and Anti-PD-1 Immunotherapy Cooperation
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2020.583382
Abstract: Immunotherapy has improved the clinical response in melanoma patients, although a relevant percentage of patients still cannot be salvaged. The search for the immune populations that provide the best tumor control and that can be… read more here.
Keywords: anti immunotherapy; melanoma; cd8; immunotherapy ... See more keywords